Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...
Scholar Rock Holding Corporation. ( NASDAQ: SRRK) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial ...
We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...
Scholar Rock Holding Corp (NASDAQ:SRRK) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 ...
In a regulatory filing, Scholar Rock ( SRRK) CEO Jay Backstrom disclosed the sale of 18,372 common shares of the company on February 18 at a price of $36.829 per share. Published first on TheFly – the ...
Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) today. The company’s ...
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...
The last time I wrote about Scholar Rock (NASDAQ:SRRK) it was with respect to a Seeking Alpha article entitled as "Scholar Rock: SMA Program Strides Forward With Positive Clinical Data".
Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have been assigned a consensus rating of “Buy” from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results